Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (NASDAQ:MRNA) will host a live conference call on May 4, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial results and provide a corporate update. Investors can join the call by dialing 866-922-5185 (domestic) or 409-937-8950 (international) with conference ID 2083116. Additionally, a webcast will be available under the Investors section of Moderna's website. Over its decade of existence, Moderna has developed a diverse portfolio of mRNA-based therapeutics and vaccines, including significant contributions to the COVID-19 pandemic response.
Moderna announces the appointment of Jorge Gomez as Chief Financial Officer, effective May 9, 2022. He joins from Dentsply Sirona, where he led the global finance organization. Gomez's experience in multinational healthcare companies and his focus on sustainability aligns with Moderna's vision. The current CFO, David Meline, will retire but assist in the transition. Moderna has evolved into a global commercial entity specializing in mRNA therapeutics and vaccines, following significant advancements in science, technology, and manufacturing.
Moderna (NASDAQ:MRNA) announced the initiation of a Phase 1/2 clinical trial for its seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030. The study will assess the safety, reactogenicity, and immunogenicity of these vaccines targeting hemagglutinin and neuraminidase antigens. Approximately 560 participants will be enrolled, and the trial aims to produce a vaccine with broader immunity against strains recommended by the WHO, including influenza A and B viruses. Moderna's mRNA platform aims to facilitate rapid vaccine matching with circulating strains.
Moderna and IAVI have announced a collaboration to utilize mRNA technology to address critical global health issues, including HIV, tuberculosis, antimicrobial-resistant pathogens, and COVID-19.
This partnership aims to develop vaccines and antibodies, particularly targeting low-income regions. A notable project is the Phase I clinical trial of an HIV vaccine (IAVI G002), with further trials planned in South Africa and Rwanda.
The collaboration seeks to leverage the rapid production capabilities of mRNA to solve urgent public health challenges.
Summary not available.
Moderna has received FDA approval for a second booster dose of its COVID-19 vaccine, mRNA-1273, at a 50 µg dose for adults aged 50+ and immunocompromised individuals over 18. This amendment to the emergency use authorization (EUA) will enable millions to enhance their immunity as the virus evolves, particularly against the BA.2 variant. The decision is supported by data from Israel highlighting the vaccine's safety and efficacy during the Omicron surge. Moderna continues to monitor real-world data and conduct clinical trials for Omicron-specific boosters.
Moderna (MRNA) has reported significant advancements in its mRNA pipeline, including successful results from a Phase 2/3 study of its COVID-19 vaccine for children aged 6 months to under 6 years, prompting regulatory submissions. The company is also seeking FDA emergency use authorization for children aged 6 to under 12. Additionally, interim data from a Phase 2 study of its influenza vaccine candidate, mRNA-1010, shows promising immunogenicity. Moderna increased its signed purchase agreements for 2022 to $21 billion, reflecting robust demand for its vaccine products.
Moderna, Inc. (NASDAQ:MRNA) has finalized a strategic partnership with the Australian Federal Government to establish a state-of-the-art mRNA vaccine manufacturing facility in Melbourne. This facility aims to produce up to 100 million vaccine doses annually, targeting respiratory viruses including COVID-19. Construction is set to begin by late 2022 and aims for operational status by 2024. The partnership also includes job creation and support for Australia’s mRNA research ecosystem.
Moderna (NASDAQ:MRNA) released positive interim data from the Phase 2/3 KidCOVE study, showing that two 25 μg doses of mRNA-1273 for children aged 6 months to under 6 years met the primary endpoint, generating robust neutralizing antibody titers similar to adults. The vaccine demonstrated favorable safety and tolerability profiles, with mild adverse reactions primarily after the second dose. Moderna plans to submit for global regulatory approvals for mRNA-1273, including emergency use authorization for children 6 to under 12 years of age.
UMass Chan Medical School has partnered with Moderna (Nasdaq: MRNA) to conduct a study on cytomegalovirus (CMV) transmission in group childcare and educational settings in Worcester and Cambridge. The study, named CMV Transmission and Immune Tracking (CMV TransmIT), aims to analyze how CMV spreads among children and between household members, with the objective to inform potential CMV vaccine development. CMV is a common infection with serious implications, including birth defects, and the research could lead to enhanced prevention strategies. Enrollment is set to begin in fall 2022.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
